Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
NEW YORK, Feb. 15, 2018 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the RBC Capital Markets 2018 Global Healthcare Conference in New York, NY, on Wednesday, February 21, 2018 at 10:30 am ET.
The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders. Lumateperone, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company's PDE1 portfolio, ITI-214, is in development for the treatment of symptoms associated with Parkinson's disease.
Contact:
Juan Sanchez, M.D.
Vice President
Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc.
Phone: 212-923-3344
Burns McClellan, Inc.
Lisa Burns
Justin Jackson (Media)
Email: [email protected]
Phone: 212-213-0006
